cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.
Company profile
Ticker
CVRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CVRX INC
SEC CIK
Corporate docs
Subsidiaries
CVRx Switzerland LLC ...
CVRX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
11 Apr 24
S-8
Registration of securities for employees
9 Feb 24
S-8
Registration of securities for employees
9 Feb 24
10-K
2023 FY
Annual report
9 Feb 24
8-K
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
31 Jan 24
8-K
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25 Jan 24
8-K
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans
8 Jan 24
8-K
CVRx receives FDA approval for expanded labeling of Barostim
26 Dec 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
15 Dec 23
10-Q
2023 Q3
Quarterly report
31 Oct 23
Transcripts
CVRX
Earnings call transcript
2023 Q4
25 Jan 24
CVRX
Earnings call transcript
2023 Q3
26 Oct 23
CVRX
Earnings call transcript
2023 Q2
25 Jul 23
CVRX
Earnings call transcript
2023 Q1
27 Apr 23
CVRX
Earnings call transcript
2022 Q4
26 Jan 23
CVRX
Earnings call transcript
2022 Q3
2 Nov 22
CVRX
Earnings call transcript
2022 Q2
29 Jul 22
CVRX
Earnings call transcript
2022 Q1
25 Apr 22
CVRX
Earnings call transcript
2021 Q4
16 Feb 22
CVRX
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
Craig E. Palmer
27 Mar 24
4
& JOHNSON JOHNSON
6 Mar 24
4
PAUL VERRASTRO
27 Feb 24
4
PAUL VERRASTRO
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
4
Kevin Hykes
14 Feb 24
SC 13G/A
Vensana Capital I GP, LLC
6 Feb 24
4
Craig E. Palmer
6 Feb 24
4
JARED OASHEIM
6 Feb 24
4
PAUL VERRASTRO
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm | 82.99 mm |
Cash burn (monthly) | 2.61 mm | 2.25 mm | 3.18 mm | 3.74 mm | 2.71 mm | 3.50 mm |
Cash used (since last report) | 17.40 mm | 15.01 mm | 21.19 mm | 24.97 mm | 18.07 mm | 23.36 mm |
Cash remaining | 65.60 mm | 67.99 mm | 61.80 mm | 58.02 mm | 64.92 mm | 59.63 mm |
Runway (months of cash) | 25.2 | 30.2 | 19.5 | 15.5 | 24.0 | 17.0 |
Institutional ownership, Q3 2023
86.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 9 |
Closed positions | 13 |
Increased positions | 20 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 173.94 bn |
Total shares | 18.71 mm |
Total puts | 92.00 k |
Total calls | 134.60 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
JNJ Johnson & Johnson | 3.50 mm | $53.03 bn |
NEA Management | 2.37 mm | $35.96 bn |
New Enterprise Associates 10 L P | 2.20 mm | $56.00 mm |
Cooperatieve Gilde Healthcare IV U.A. | 1.83 mm | $46.63 mm |
Vensana Capital I GP | 1.71 mm | $0.00 |
Soleus Capital Master Fund | 1.01 mm | $0.00 |
BLK Blackrock | 730.92 k | $11.09 bn |
Balyasny Asset Management | 675.02 k | $10.24 bn |
Vanguard | 550.03 k | $8.34 bn |
STT State Street | 523.32 k | $7.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 151 | 35.79 | 1,229 |
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 404 | 95.75 | 1,078 |
25 Mar 24 | Craig E. Palmer | Common Stock | Option exercise | Acquire M | No | No | 0.237 | 379 | 89.82 | 674 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 151 | 35.79 | 0 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 404 | 95.75 | 0 |
25 Mar 24 | Craig E. Palmer | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.237 | 379 | 89.82 | 0 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 5.141 | 79 | 406.14 | 4,103,430 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 3.955 | 252 | 996.66 | 4,103,351 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 142 | 168.41 | 4,103,099 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 442 | 524.21 | 4,102,957 |
News
Analyst Expectations For CVRx's Future
26 Jan 24
Piper Sandler Maintains Overweight on CVRx, Raises Price Target to $33
26 Jan 24
JP Morgan Maintains Overweight on CVRx, Raises Price Target to $36
26 Jan 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Jan 24
CVRx Q4 EPS $(0.44) Beats $(0.54) Estimate, Sales $11.30M Beat $11.14M Estimate
25 Jan 24
Press releases
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
16 Apr 24
CVRx announces availability of additional data supporting long-term benefits of Barostim
15 Apr 24
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
25 Jan 24